A method for measuring a marker indicative of the exposure of a patient to nicotine; a kit for measuring such a marker
CA 2404540 A1 · Owner: Cormier, Anne · Inventors: Grailhe, Regis Christian; Changeux, Jean Pierre; Cormier, Anne
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention demonstrates that epibatidine binds to nicotinic receptors on leukocytes. Epibatidine is a sensitive detector of increases in the, number of nicotinic receptors expressed by a cell. Epibatidine binds to the leukocytes of smokers, but does not bind to the leukocytes of non-smokers. Both, in vivo and ex vivo nicotine exposure induces epibatidine receptor expression. Epibatidine binding to leukocytes reflects epibatidine binding in the central nervous system, which in turn reflects nicotine-induced effects on the central nervous system. Epibatidine binding assays in peripheral blood leukocytes can be used to evaluate an individual's exposure to and dependence on, …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 20, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 20, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 20, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.